Trastuzumab use for metastatic breast cancer in pregnancy.
BACKGROUND
Trastuzumab is approved for first-line treatment for breast cancer in combination with docetaxel for stage 2 tumors positive for human epidermal growth factor receptor 2. The effects of trastuzumab on the fetus are mostly unknown.


METHODS
Our case report focuses on a woman who was treated for invasive ductal carcinoma 1 year before pregnancy. She presented at 20 weeks of gestation with metastases and was treated with docetaxel and trastuzumab. She underwent two cycles of chemotherapy, and an ultrasound scan at 30 weeks showed anhydramnios. There was no history of ruptured membranes. Reappearance of amniotic fluid was noted at 33 weeks of gestation, 7 weeks after cessation of treatment.


CONCLUSIONS
Treatment with trastuzumab during midgestation may be associated with anhydramnios.
Sekar
Renuka
R
Department of Obstetrics and Gynecology, Faculty of Medical and Health Science, University of Auckland, Auckland, New Zealand. renukas@adhb.govt.nz
Stone
Peter R
PR
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D020516:Brachial Plexus Neuropathies / Q000188:drug therapy; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D000077143:Docetaxel; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D009367:Neoplasm Staging; D016104:Oligohydramnios / Q000139:chemically induced*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy* / Q000473:pathology; D011256:Pregnancy Outcome; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D000068878:Trastuzumab